- Trial phase
- Phase 2
- Time to market
- If Part B data are positive in 2027, a Phase 3 program would follow, meaning potential approval is likely several years away (2029 or later), assuming successful trials.
- Why 6/10
- SPY230 has no PDUFA date (still Phase 2). The next hard catalyst is the SKYLINE Part B induction data readout, expected in Q3 2027 (roughly 10 months away). SPY230 is one of three combination arms in Part B, and the combination strategy is central to Spyre's thesis, but the company also has other pipeline programs (SPY120, SPY130, SPY772), so the score reflects a major but not single-asset binary event.
The next major catalyst for SPY230 is the SKYLINE Part B induction data readout, expected in Q3 2027 (roughly 10 months away). Positive data showing superiority of the SPY230 combination over its constituent monotherapies would validate Spyre's combination strategy and likely drive the stock higher. Negative or equivocal data would undermine the central thesis and could trigger significant downside given the premium valuation.
Price Chart
Executive Summary
SPY230 is a Phase 2 combination antibody therapy from Spyre Therapeutics (NASDAQ: SYRE) that pairs an anti-TL1A antibody (SPY002) with an anti-IL-23 antibody (SPY003) for inflammatory bowel disease. All three monotherapy components achieved positive proof-of-concept in Part A of the SKYLINE trial. The combination arms (SPY120, SPY130, and SPY230) are now enrolling in Part B, with induction data expected in Q3 2027. Spyre has a strong cash position ($1.47B pro forma) and broad institutional support, but faces intense competition in the TL1A space from Merck (Phase 3), Roche, and others. The stock trades near $99 with a Strong Buy analyst consensus and a mean price target of $122.53.
How It Works
SPY230 is a combination of two engineered antibodies given together as a single injection. One antibody (SPY002) blocks TL1A, a protein that drives inflammation and tissue scarring in the gut. The other (SPY003) blocks IL-23, another inflammatory signal. By hitting both targets at once, the drug aims to shut down inflammatory bowel disease (IBD) more completely than blocking either pathway alone. The antibodies are engineered to last longer in the body (extended half-life), potentially allowing patients to receive injections only once every 3 to 6 months instead of every few weeks.
Trial Status
SPY230 is being evaluated in Part B of the Phase 2 SKYLINE-UC platform trial (NCT07012395) in moderate-to-severe ulcerative colitis. Part A (open-label monotherapy proof-of-concept) completed with positive data for all three component antibodies. Part B is actively enrolling and will test SPY120, SPY130, and SPY230 combinations at high doses versus monotherapies and placebo using a factorial design. The company reported that Part B enrollment is ahead of schedule.
The Two-Sided Case
Upcoming Catalysts
- SKYLINE Part B induction data readout for SPY120, SPY130, and SPY230 combinations, expected in Q3 2027
- SKYLIGHT Phase 2 trial in hidradenitis suppurativa (SPY772), topline data expected late 2027 or early 2028
- Potential partnership or licensing interest given the competitive TL1A/IL-23 landscape
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Spyre Therapeutics, Inc. PRESS-RELEASE SYRE ·Originating report